中文 (香港)
Overview
MonoTx® has developed an integrated human umbilical cord blood (UCB)–derived therapeutic platform that enables the scalable production of clinical-grade mononuclear cells (MNCs), plasma-derived exosomes, and red blood cell fraction from qualified donor material. The platform combines AABB-accredited cord blood banking, closed-system automated cell separation, and a proprietary PEG-based exosome isolation technology — now protected by a granted US patent — to generate highly potent cell and exosome products from the youngest source of blood, with demonstrated regenerative and rejuvenative activities across multiple therapeutic areas.
The platform is built on a foundational scientific discovery: UCB exosomes are naturally enriched with microRNA that acts as a master regulator of cellular senescence. UCB exosomes upregulates CDK1 to restore G2/M cell cycle progression, suppresses senescence markers, restore proliferation markers, and rebuilds nuclear integrity while reducing DNA damage. This mechanism-defined approach distinguishes MonoTx® from empirically developed exosome products and provides a molecular rationale for therapeutic activity across ophthalmology, neurology, wound healing, and anti-aging applications.
This vertically integrated approach — from accredited cord blood bank through proprietary manufacturing to characterized therapeutic products — positions MonoTx® to advance multiple cell-based and cell-free regenerative therapies.
Wise Young, PhD, MD
Chairman & Laboratory Director
Wise Young, PhD, MD — Chairman & Laboratory Director Founder of MonoTx®, Distinguished Professor at Rutgers University, and Director of the W.M. Keck Center for Collaborative Neuroscience. Dr. Young pioneered cord blood MNC transplantation for spinal cord injury, established high‑dose methylprednisolone as the first effective SCI therapy, and co‑founded Acorda Therapeutics, Inc.
Kenneth Giacin
CEO
Kenneth Giacin — Chief Executive Officer Co‑founder of MonoTx® with 25 years at Johnson & Johnson and 16 years in cord blood banking. Former Chairman and CEO of StemCyte, he has led global operations and serves on boards including the Cord Blood Association and NIH advisory committees.
John Horvath
Director
John Horvath — Director Partner at EisnerAmper, LLP and CPA with 30+ years in accounting. Co‑founder of The Bank of Princeton, now a NASDAQ‑listed institution, with extensive experience in capital raises and mergers.
Malcolm Wall Morris
Director
Malcolm Wall Morris — Director Co‑founder and CEO of EMA Aesthetics Ltd., a global aesthetics company. Led strategic partnerships with multinational healthcare firms and drove corporate transformations across 25 countries. EMA Aesthetics invested in MonoTx® in 2026, securing board representation.
Mark Pinney
Chief Financial Officer
Mark Pinney — Chief Financial Officer Financial executive with extensive biotech and technology experience. Former CFO of Acorda Therapeutics and TACODA, co‑founder of Real Media, and CFA charterholder. Holds advanced degrees from Chicago Booth, Columbia, and Exeter.
Wendy Shong Cheng, PhD, PMP, CCRA
Chief Operating Officer
Wendy Shong Cheng, PhD, PMP, CCRA — Chief Operating Officer PhD in Chemistry from HKUST, PMP and CCRA certified. Former VP of the China Spinal Cord Injury Network, where she managed the first cord blood MNC transplant trials for chronic SCI.
Dongming Sun, MD, PhD
Chief Scientific Officer
Dongming Sun, MD, PhD — Chief Scientific Officer Assistant Research Professor at Rutgers University with 20+ years in neuroscience and stem cell research. Expert in SCI models and CNS regeneration, with 40+ publications and ~2,000 citations.
Chi Kong Li, MD
Medical Director
Chi Kong Li, MD — Medical Director Professor and Chief of Hematology/Oncology/BMT at CUHK. Specialist in childhood leukemia and stem cell transplantation, introducing double‑unit cord blood transplantation and MIBG therapy. Former President of the Asia Continent of the International Society of Pediatric Oncology.
Tak Yeung Leung, MD
Medical Director for HPC, Apheresis
Tak Yeung Leung, MD — Medical Director for HPC, Apheresis
Clinical Professor at CUHK and Director of Maternal Fetal Medicine, Prof. Leung is internationally recognized for expertise in fetal diagnosis and therapy, pioneering advanced interventions such as fetoscopic laser treatment for twin‑twin transfusion syndrome, FETO for congenital diaphragmatic hernia, and in‑utero procedures.
Mr. Charles Lu, MBA
Chief Commercial Officer
Charles Lu, MBA — Chief Commercial Officer 25+ years in pharmaceuticals and stem cell banking. Built a successful pharmacy chain in Taiwan and later led StemCyte Taiwan and U.S. operations. Serves on boards including the Cord Blood Association and NMDP.
Our Facility
MonoTx™ facility at the Hong Kong Science Park is designed and equipped for umbilical cord blood mononuclear cell (MNC) processing, testing, storage, and distribution for clinical and research applications.
The facility has a Grade C cleanroom and Grade A biological safety cabinets to process cord blood. The cleanroom is NEBB certified and complies with ISO14644 air quality requirements.
The facility is equipped to test cord blood products. Each processed cord blood unit is assessed for cell types and cell numbers, cell viability, ability to produce colony forming units, and to determine microbial contamination.
